BRD4 and urothelial carcinoma: Combinations of HDIs with e.g., thienotriazolodiazepine (JQ1), an inhibitor of bromodomain-containing acetylation reader proteins like bromodomain-containing protein 4 (BRD4), have shown efficacy in several cancer types, including urothelial carcinoma [9].